CN102939292A - 螺环化合物及其作为治疗剂和诊断探针的用途 - Google Patents

螺环化合物及其作为治疗剂和诊断探针的用途 Download PDF

Info

Publication number
CN102939292A
CN102939292A CN2011800239958A CN201180023995A CN102939292A CN 102939292 A CN102939292 A CN 102939292A CN 2011800239958 A CN2011800239958 A CN 2011800239958A CN 201180023995 A CN201180023995 A CN 201180023995A CN 102939292 A CN102939292 A CN 102939292A
Authority
CN
China
Prior art keywords
oxa
morpholino
hept
azaspiro
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800239958A
Other languages
English (en)
Chinese (zh)
Inventor
V.克米尔贾诺维奇
N.克米尔贾诺维奇
B.吉泽
M.维曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Basel
Original Assignee
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Basel filed Critical Universitaet Basel
Publication of CN102939292A publication Critical patent/CN102939292A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
CN2011800239958A 2010-03-15 2011-03-11 螺环化合物及其作为治疗剂和诊断探针的用途 Pending CN102939292A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1004200.0A GB201004200D0 (en) 2010-03-15 2010-03-15 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
GB1004200.0 2010-03-15
PCT/IB2011/051047 WO2011114275A1 (en) 2010-03-15 2011-03-11 Spirocyclic compounds and their use as therapeutic agents and diagnostic probes

Publications (1)

Publication Number Publication Date
CN102939292A true CN102939292A (zh) 2013-02-20

Family

ID=42261530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800239958A Pending CN102939292A (zh) 2010-03-15 2011-03-11 螺环化合物及其作为治疗剂和诊断探针的用途

Country Status (15)

Country Link
US (1) US20130040934A1 (https=)
EP (1) EP2547684A1 (https=)
JP (1) JP2013522286A (https=)
KR (1) KR20130086520A (https=)
CN (1) CN102939292A (https=)
AU (1) AU2011228703A1 (https=)
BR (1) BR112012023320A2 (https=)
CA (1) CA2791737A1 (https=)
GB (1) GB201004200D0 (https=)
MX (1) MX2012010655A (https=)
NZ (1) NZ602292A (https=)
RU (1) RU2012143689A (https=)
SG (1) SG184062A1 (https=)
WO (1) WO2011114275A1 (https=)
ZA (1) ZA201206580B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103483345A (zh) * 2013-09-25 2014-01-01 中山大学 Pi3k 激酶抑制剂、包含其的药物组合物及其应用
CN104557871A (zh) * 2013-10-28 2015-04-29 上海汇伦生命科技有限公司 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CN105431420A (zh) * 2013-05-01 2016-03-23 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
CN108191837A (zh) * 2018-01-10 2018-06-22 贵州医科大学 PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
CN112584833A (zh) * 2018-08-01 2021-03-30 亚瑞克西斯制药公司 杂环螺化合物及其用于治疗癌症的使用方法
US12234244B2 (en) 2013-10-10 2025-02-25 Araxes Pharma Llc Substituted piperazines as inhibitors of KRAS G12C

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2970240B1 (en) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
LT3134432T (lt) 2014-04-25 2020-04-10 Bluebird Bio, Inc. Mnd promotorius chimerinių antigenų receptoriams
NZ725201A (en) 2014-04-25 2018-05-25 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
DK3212637T3 (da) 2014-10-31 2021-07-12 Indivior Uk Ltd Dopamin-d3-receptorantagonistforbindelser
EA036379B1 (ru) 2014-12-12 2020-11-02 Блубёрд Био, Инк. Химерные антигенные рецепторы к bcma
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
EP3231799A1 (en) * 2016-04-14 2017-10-18 Universität Basel 4-(azetidin-1-yl)pyrimidine derivatives with anti-mitotic and anti-proliferative activity
KR20240005168A (ko) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포 조성물
CA3044771A1 (en) * 2016-12-21 2018-06-28 Japan Tobacco Inc. Crystalline forms of a janus kinase inhibitor
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
JP7340519B2 (ja) * 2017-11-06 2023-09-07 メッドシャイン ディスカバリー インコーポレイテッド ｍＴＯＲＣ１／２二重阻害剤としてのピリドピリミジン系化合物
WO2021113506A1 (en) * 2019-12-04 2021-06-10 Chdi Foundation, Inc. Atm kinase inhibitors and compositions and methods of use thereof
JP7554829B2 (ja) * 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
JP7654071B2 (ja) * 2020-10-20 2025-03-31 アムジエン・インコーポレーテツド 複素環スピロ化合物及び使用方法
US20250206729A1 (en) * 2023-12-22 2025-06-26 Deciphera Pharmaceuticals, Llc Dual raf and tubulin inhibitors and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090167A2 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
CN1310907C (zh) * 2001-04-27 2007-04-18 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤药
WO2007066103A1 (en) * 2005-12-09 2007-06-14 Astrazeneca Ab Pyrimidine derivatives as class i pi3k inhibitor
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
CN101563340A (zh) * 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
WO2009143317A1 (en) * 2008-05-23 2009-11-26 Wyeth Triazine compounds as p13 kinase and mtor inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1310907C (zh) * 2001-04-27 2007-04-18 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤药
WO2006090167A2 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
WO2007066103A1 (en) * 2005-12-09 2007-06-14 Astrazeneca Ab Pyrimidine derivatives as class i pi3k inhibitor
CN101563340A (zh) * 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
WO2008098058A1 (en) * 2007-02-06 2008-08-14 Novartis Ag Pi 3-kinase inhibitors and methods of their use
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
WO2009143317A1 (en) * 2008-05-23 2009-11-26 Wyeth Triazine compounds as p13 kinase and mtor inhibitors

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105431420A (zh) * 2013-05-01 2016-03-23 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
CN110003178A (zh) * 2013-05-01 2019-07-12 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
CN105431420B (zh) * 2013-05-01 2019-08-13 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
CN110003178B (zh) * 2013-05-01 2022-02-25 豪夫迈·罗氏有限公司 二杂芳基化合物及其用途
CN103483345A (zh) * 2013-09-25 2014-01-01 中山大学 Pi3k 激酶抑制剂、包含其的药物组合物及其应用
CN103483345B (zh) * 2013-09-25 2016-07-06 中山大学 Pi3k激酶抑制剂、包含其的药物组合物及其应用
US12234244B2 (en) 2013-10-10 2025-02-25 Araxes Pharma Llc Substituted piperazines as inhibitors of KRAS G12C
CN104557871A (zh) * 2013-10-28 2015-04-29 上海汇伦生命科技有限公司 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CN104557871B (zh) * 2013-10-28 2017-05-03 上海汇伦生命科技有限公司 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
CN108191837A (zh) * 2018-01-10 2018-06-22 贵州医科大学 PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
CN112584833A (zh) * 2018-08-01 2021-03-30 亚瑞克西斯制药公司 杂环螺化合物及其用于治疗癌症的使用方法

Also Published As

Publication number Publication date
EP2547684A1 (en) 2013-01-23
US20130040934A1 (en) 2013-02-14
AU2011228703A1 (en) 2012-09-20
MX2012010655A (es) 2012-10-05
RU2012143689A (ru) 2014-04-20
NZ602292A (en) 2014-08-29
CA2791737A1 (en) 2011-09-22
GB201004200D0 (en) 2010-04-28
KR20130086520A (ko) 2013-08-02
WO2011114275A1 (en) 2011-09-22
SG184062A1 (en) 2012-10-30
BR112012023320A2 (pt) 2016-05-24
ZA201206580B (en) 2013-05-29
JP2013522286A (ja) 2013-06-13

Similar Documents

Publication Publication Date Title
CN102939292A (zh) 螺环化合物及其作为治疗剂和诊断探针的用途
JP6928185B2 (ja) 縮合環化合物
CN102209714B (zh) 三嗪、嘧啶和吡啶类似物和它们作为治疗剂和诊断探针的应用
JP5512545B2 (ja) Ａｋｔタンパク質キナーゼ阻害剤としてのピリミジルシクロペンタン類
US10428080B2 (en) TBK/IKK inhibitor compounds and uses thereof
ES2886577T3 (es) Compuestos macrólidos como inhibidores de irak1/4 y sus usos
CN101516891B (zh) 作为akt蛋白激酶抑制剂的二氢噻吩并嘧啶
CN109219604A (zh) 四氢异喹啉雌激素受体调节剂及其用途
ES2841452T3 (es) Macrociclos de piridazinona como inhibidores de IRAK y sus usos
WO2022265993A1 (en) Urea derivatives which can be used to treat cancer
CA3092470A1 (en) Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CA3105721A1 (en) Fused pyrazine derivatives as a2a / a2b inhibitors
CN103288753A (zh) 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶
CN103201277A (zh) 哒嗪酮、其制备方法及使用方法
CN101918403A (zh) 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
MX2010012583A (es) Compuestos inhibidores de purina pi3k y métodos de uso.
CN106220614A (zh) 吡啶酮/吡嗪酮、其制备方法及使用方法
CA2615946A1 (en) Pyrazolo pyrimidines useful as aurora kinase inhibitors
KR20140129266A (ko) Smac 모방체로서의 6-알키닐 피리딘
EP3898627A1 (en) Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
EP4561562A2 (en) Tricyclic aryl derivatives, and compositions and methods thereof
CN121311486A (zh) Erbb2抑制剂
HK1181770A (en) Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
HK1231462B (zh) 吡啶酮/吡嗪酮、其制备方法及使用方法
HK40043591B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181770

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20160106

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1181770

Country of ref document: HK